ONC (BeOne Medicines) Cyclically Adjusted PS Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ONC BeOne Medicines Ltd ONC
81 GF Score
Price $350.84
GF Value $381.92
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is BeOne Medicines Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


BeOne Medicines  (NAS:ONC) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


BeOne Medicines Cyclically Adjusted PS Ratio Related Terms


BeOne Medicines Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for BeOne Medicines's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BeOne Medicines Cyclically Adjusted PS Ratio Chart

BeOne Medicines Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 47.54 25.62 17.30 19.74

BeOne Medicines Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.92 21.80 17.88 15.98 14.03

ONC vs RVMD, MRNA, ALNY: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, BeOne Medicines's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BeOne Medicines Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeOne Medicines's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where BeOne Medicines's Cyclically Adjusted PS Ratio falls into.


ONC
81GF Score
BeOne Medicines Ltd ONC
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BeOne Medicines Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

BeOne Medicines's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, BeOne Medicines's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=14.749/108.5600*108.5600
=14.749

Current CPI (Jun. 2026) = 108.5600.

BeOne Medicines Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.000 99.604 0.000
201612 0.000 99.380 0.000
201703 0.000 100.040 0.000
201706 0.000 100.285 0.000
201709 3.696 100.254 4.002
201712 0.306 100.213 0.331
201803 0.550 100.836 0.592
201806 0.874 101.435 0.935
201809 0.902 101.246 0.967
201812 0.981 100.906 1.055
201903 1.314 101.571 1.404
201906 4.062 102.044 4.321
201909 0.830 101.396 0.889
201912 0.928 101.063 0.997
202003 0.671 101.048 0.721
202006 0.844 100.743 0.909
202009 1.036 100.585 1.118
202012 1.096 100.241 1.187
202103 6.251 100.800 6.732
202106 1.640 101.352 1.757
202109 2.228 101.533 2.382
202112 2.256 101.776 2.406
202203 2.997 103.205 3.153
202206 3.302 104.783 3.421
202209 3.718 104.835 3.850
202212 3.657 104.666 3.793
202303 4.290 106.245 4.383
202306 5.625 106.576 5.730
202309 7.306 106.570 7.442
202312 6.138 106.461 6.259
202403 7.197 107.355 7.278
202406 8.864 107.991 8.911
202409 9.535 107.468 9.632
202412 10.576 107.128 10.717
202503 10.064 107.722 10.142
202506 11.727 108.075 11.780
202509 12.349 107.710 12.446
202512 13.042 107.200 13.207
202603 13.112 108.060 13.173
202606 14.749 108.560 14.749

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is BeOne Medicines (ONC) Overvalued in 2026?

Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued. The current stock price of $350.84 is trading 8.1% below its estimated GF Value™ of $381.92. GuruFocus considers BeOne Medicines to be Fairly Valued.

Key valuation signals for ONC:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: $381.92 vs. price of $350.84 (8.1% below fair value)
  • GF Score™: 81/100 with 5 warning signs

No single metric tells the full story. See the ONC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BeOne Medicines Business Description

Address c/o BeOne Medicines I GmbH, 94 Aeschengraben 27, 21st Floor, Basel, CHE, 4051
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
81GF Score

Get the complete analysis for ONC

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$350.84
Price
$381.92
GF Value